Core Viewpoint - The article discusses the limitations of Paclitaxel (PTX) as a chemotherapy drug and highlights recent advancements in drug delivery systems that enhance its efficacy and safety in treating various cancers, particularly triple-negative breast cancer and pancreatic cancer [3][4][5]. Group 1: Limitations of Current Paclitaxel Formulations - Paclitaxel is a powerful chemotherapy drug used for multiple cancers but has significant limitations due to poor solubility, unfavorable pharmacokinetics, and severe side effects [3]. - The FDA has only approved two formulations of Paclitaxel: Taxol and Abraxane. Taxol, while improving solubility, can cause severe allergic reactions due to its excipients, necessitating pre-treatment with antihistamines and steroids [4]. - Abraxane, a nanoparticle formulation, is safer than Taxol but does not significantly improve pharmacokinetics or tumor delivery, leading to suboptimal clinical outcomes [4]. Group 2: Recent Research and Innovations - A research team from the University of Arizona developed a novel sphingolipid-derived Paclitaxel nanovesicle called Paclitaxome, which improves pharmacokinetics and enhances anti-tumor efficacy while reducing bone marrow suppression toxicity in mouse models of metastatic triple-negative breast cancer and pancreatic cancer [6][10]. - The study introduced a functionalized delivery system that incorporates a super pH-sensitive probe and CD47 peptide to enhance tumor penetration and reduce immune system phagocytosis, resulting in improved therapeutic outcomes [10]. - The new Paclitaxel formulation demonstrated superior therapeutic effects compared to previously reported Paclitaxel nanocarriers and has potential applications in other drug delivery systems, such as camptothecin [12].